Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425594 | 1.00 | HCAR3 (0.43) | HCAR3JAK1JAK3CREBBPFLT3 | |
| SCHEMBL2425596 | 1.00 | HCAR3 (0.43) | HCAR3JAK1JAK3CREBBPFLT3 | |
| SCHEMBL2426799 | 0.87 | HCAR3 (0.55) | HCAR3CREBBPFLT3HSP90AA1 | |
| SCHEMBL2426534 | 0.84 | HCAR3 (0.57) | HCAR3CREBBPFLT3 | |
| SCHEMBL2426793 | 0.84 | HCAR3 (0.57) | HCAR3CREBBPFLT3 | |
| SCHEMBL2424448 | 0.83 | HCAR3 (0.56) | HCAR3CREBBPFLT3 | |
| SCHEMBL2422536 | 0.82 | HSP90AA1 (0.53) | HCAR3HSP90AA1HSP90AB1 | |
| SCHEMBL2422533 | 0.82 | HSP90AA1 (0.53) | HCAR3HSP90AA1HSP90AB1 | |
| SCHEMBL2427377 | 0.81 | CREBBP (0.51) | HCAR3JAK1JAK3CREBBPFLT3 | |
| SCHEMBL2425142 | 0.77 | JAK2 (0.49) | HCAR3JAK1JAK3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910168-B | Tropane compounds | EXELIXIS INC | 2014-07-30 | — | — | CN | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | HCAR3 1036/4885JAK1 3214/4885JAK3 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.